Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

Autor: Avendano-Sola, C, Ramos-Martinez, A, Munez-Rubio, E, Ruiz-Antoran, B, de Molina, RM, Torres, F, Fernandez-Cruz, A, Calderon-Parra, J, Payares-Herrera, C, de Santiago, AD, Romera-Martinez, I, Pintos, I, Lora-Tamayo, J, Mancheno-Losa, M, Paciello, ML, Martinez-Gonzalez, AL, Vidan-Estevez, J, Nunez-Orantos, MJ, Saez-Serrano, MI, Porras-Leal, ML, Jarilla-Fernandez, MC, Villares, P, de Oteyza, JP, Ramos-Garrido, A, Blanco, L, Madrigal-Sanchez, ME, Rubio-Batlles, M, Velasco-Iglesias, A, Pano-Pardo, JR, Moreno-Chulilla, JA, Muniz-Diaz, E, Casas-Flecha, I, Perez-Olmeda, M, Garcia-Perez, J, Alcami, J, Bueno, JL, Duarte, RF, Bösch A., Villegas da Ros, Carolina

Publikováno v: JOURNAL OF CLINICAL INVESTIGATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

BACKGROUND. Passive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19. Evidence from controlled clinical trials is inconclusive. METHODS. We conducted a randomized, open-label, controlled clinical trial at 27 hospitals

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::20a7ca34c43a61843ef7a40763d398f1
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8010

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.

Autor: Gonzalez-Perez M; Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain., Montes-Casado M; Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain., Conde P; Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain., Cervera I; Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain., Baranda J; Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain., Berges-Buxeda MJ; Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain., Perez-Olmeda M; Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain., Sanchez-Tarjuelo R; Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Utrero-Rico A; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Lozano-Ojalvo D; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Torre D; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Schwarz M; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Guccione E; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Camara C; Department of Immunology, Hospital La Paz, Madrid, Spain., Llópez-Carratalá MR; Department of Nephrology, Hospital Puerta de Hierro, Madrid, Spain., Gonzalez-Parra E; Department of Nephrology, Instituto de Investigación Sanitaria (IIS)-Fundación Jimenez Díaz, Madrid, Spain., Portoles P; Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.; Presidencia, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain., Ortiz A; Department of Nephrology, Instituto de Investigación Sanitaria (IIS)-Fundación Jimenez Díaz, Madrid, Spain., Portoles J; Department of Nephrology, Hospital Puerta de Hierro, Madrid, Spain., Ochando J; Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2022 Mar 23; Vol. 13, pp. 845882. Date of Electronic Publication: 2022 Mar 23 (Print Publication: 2022).